In contrast, in vivo studies typically focus on tau aggregation in mice or post‐mortem brain tissue, which are closer to tauopathy development; nevertheless, in vivo studies are often hindered by the lack of detection methods with satisfactory sensitivity and specificity in complex samples, as well as the inability to probe tau aggregation in real time. The gene discussed is MAPT; the disease is tauopathy.